Quarterly ResultMay 13, 2026, 04:23 PM
GRI Bio Q1 Net Loss Narrows to $2.0M; Cash $11.0M
AI Summary
GRI Bio, Inc. reported a reduced net loss of $2.0 million for Q1 2026, down from $3.0 million in Q1 2025, primarily due to a significant decrease in research and development expenses. The company's cash and cash equivalents increased to $11.0 million as of March 31, 2026, bolstered by $6.8 million in gross proceeds from its At The Market (ATM) offering. Additionally, the Phase 2a clinical trial for its lead product candidate, GRI-0621, for idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints, showing positive safety and anti-fibrotic effects. Despite improved liquidity, the company noted substantial doubt about its ability to continue as a going concern without further capital.
Key Highlights
- Net loss for Q1 2026 narrowed to $2.0 million from $3.0 million in Q1 2025.
- Research and development expenses decreased by 78% to $0.4 million in Q1 2026.
- General and administrative expenses increased by 16% to $1.6 million in Q1 2026.
- Cash and cash equivalents rose to $11.0 million as of March 31, 2026.
- Total stockholders' equity increased to $10.5 million as of March 31, 2026.
- Raised $6.8 million in gross proceeds from the ATM offering during Q1 2026.
- GRI-0621 Phase 2a clinical trial for IPF met primary and secondary endpoints.
- Company's cash is sufficient into Q2 2027 for preliminary Phase 2b work.